360 related articles for article (PubMed ID: 20869852)
1. Emergence of carbapenem resistance due to porin loss in an extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy.
Webster DP; Gaulton T; Woodford N; Pike R; Turton J; Perry C; Bowler IC
Int J Antimicrob Agents; 2010 Dec; 36(6):575-6. PubMed ID: 20869852
[No Abstract] [Full Text] [Related]
2. In vivo selection of carbapenem-resistant Klebsiella pneumoniae by OmpK36 loss during meropenem treatment.
Song W; Suh B; Choi JY; Jeong SH; Jeon EH; Lee YK; Hong SG; Lee K
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):447-9. PubMed ID: 19766430
[TBL] [Abstract][Full Text] [Related]
3. Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia.
Palasubramaniam S; Muniandy S; Navaratnam P
J Microbiol Immunol Infect; 2009 Apr; 42(2):129-33. PubMed ID: 19597644
[TBL] [Abstract][Full Text] [Related]
4. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Park YJ; Yu JK; Park KG; Park YG; Lee S; Kim SY; Jeong SH
Diagn Microbiol Infect Dis; 2011 Sep; 71(1):87-9. PubMed ID: 21397426
[TBL] [Abstract][Full Text] [Related]
6. Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
Padilla E; Alonso D; Doménech-Sánchez A; Gomez C; Pérez JL; Albertí S; Borrell N
Antimicrob Agents Chemother; 2006 Jun; 50(6):2258-60. PubMed ID: 16723600
[TBL] [Abstract][Full Text] [Related]
7. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
8. Endoscopy-associated transmission of carbapenem-resistant Klebsiella pneumoniae producing KPC-2 beta-lactamase.
Naas T; Cuzon G; Babics A; Fortineau N; Boytchev I; Gayral F; Nordmann P
J Antimicrob Chemother; 2010 Jun; 65(6):1305-6. PubMed ID: 20382724
[No Abstract] [Full Text] [Related]
9. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
Leavitt A; Navon-Venezia S; Chmelnitsky I; Schwaber MJ; Carmeli Y
Antimicrob Agents Chemother; 2007 Aug; 51(8):3026-9. PubMed ID: 17562800
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of carbapenem-resistant Enterobacteriaceae isolates from Korea.
Kim SY; Shin J; Shin SY; Ko KS
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):486-90. PubMed ID: 23688521
[TBL] [Abstract][Full Text] [Related]
11. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
Lee CH; Chu C; Liu JW; Chen YS; Chiu CJ; Su LH
J Antimicrob Chemother; 2007 Aug; 60(2):410-3. PubMed ID: 17576696
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development.
Mena A; Plasencia V; García L; Hidalgo O; Ayestarán JI; Alberti S; Borrell N; Pérez JL; Oliver A
J Clin Microbiol; 2006 Aug; 44(8):2831-7. PubMed ID: 16891499
[TBL] [Abstract][Full Text] [Related]
13. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss.
Gülmez D; Woodford N; Palepou MF; Mushtaq S; Metan G; Yakupogullari Y; Kocagoz S; Uzun O; Hascelik G; Livermore DM
Int J Antimicrob Agents; 2008 Jun; 31(6):523-6. PubMed ID: 18339523
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro killing of carbapenems and aztreonam against Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.
Panagiotakopoulou A; Daikos GL; Miriagou V; Loli A; Tzelepi E; Tzouvelekis LS
Int J Antimicrob Agents; 2007 Mar; 29(3):360-2. PubMed ID: 17223016
[No Abstract] [Full Text] [Related]
15. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study.
Kritsotakis EI; Tsioutis C; Roumbelaki M; Christidou A; Gikas A
J Antimicrob Chemother; 2011 Jun; 66(6):1383-91. PubMed ID: 21454344
[TBL] [Abstract][Full Text] [Related]
16. Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tübingen, Germany.
Gröbner S; Linke D; Schütz W; Fladerer C; Madlung J; Autenrieth IB; Witte W; Pfeifer Y
J Med Microbiol; 2009 Jul; 58(Pt 7):912-922. PubMed ID: 19502377
[TBL] [Abstract][Full Text] [Related]
17. Re: A VIM-1-metallo-beta-lactamase-producing Klebsiella pneumoniae clinical isolate in an acute hospital in Germany.
Shah PM
Int J Antimicrob Agents; 2009 Oct; 34(4):381. PubMed ID: 19502012
[No Abstract] [Full Text] [Related]
18. Plasmid-mediated carbapenem-hydrolysing β-lactamase KPC-2 in a Klebsiella pneumoniae isolate from Switzerland.
Poirel L; Lienhard R; Potron A; Malinverni R; Siegrist HH; Nordmann P
J Antimicrob Chemother; 2011 Mar; 66(3):675-6. PubMed ID: 21193473
[No Abstract] [Full Text] [Related]
19. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases.
Conejo MC; Hernández JR; Pascual A
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):343-5. PubMed ID: 18339509
[TBL] [Abstract][Full Text] [Related]
20. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel.
Samra Z; Ofir O; Lishtzinsky Y; Madar-Shapiro L; Bishara J
Int J Antimicrob Agents; 2007 Dec; 30(6):525-9. PubMed ID: 17931835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
